JNBA Financial Advisors Has $27,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

JNBA Financial Advisors decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 78.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 351 shares of the company’s stock after selling 1,305 shares during the quarter. JNBA Financial Advisors’ holdings in AstraZeneca were worth $27,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. McClarren Financial Advisors Inc. raised its position in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter worth $26,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca during the 1st quarter worth $29,000. RFP Financial Group LLC boosted its holdings in AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after acquiring an additional 178 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 3.7 %

Shares of AstraZeneca stock opened at $63.85 on Thursday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The firm has a market capitalization of $197.97 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company’s fifty day moving average price is $78.45 and its two-hundred day moving average price is $78.75.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen raised their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.